Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag is produced by co-expression of IL-12B and IL-12A, has a calculated MW of 36.6 kDa (IL-12B) and 23.8 kDa (IL-12A). Subunit IL-12B is fused with polyhistidine tag at the C-terminus and subunit IL-12A is fused with flag tag at the C-terminus. The reducing (R) heterodimer protein migrates as 45 kDa (IL12B) and 38-43 kDa (IL12A) respectively due to glyosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) at 0.5 μg/mL (100 μL/well) can bind Anti-IL23A & IL12B MAb (P40 domain) with a linear range of 0.2-2 ng/mL (QC tested).
Immobilized Biotinylated Human IL-12 R beta 1, Fc,Avitag (Cat. No. ILB-H82F7) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with a linear range of 0.039-0.625 μg/mL (Routinely tested).
Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Anti-IL23A & IL12B MAb (P40 domain) on Protein A Biosensor, can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 1.07 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) on HIS1K Biosensor, can bind Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) with an affinity constant of 92.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) stimulates the proliferation of PHA-P activated PBMC. The ED50 for this effect is 0.05 ng/mL (Routinely tested).
Price(EUR) : €170.00
Price(EUR) : €380.00
Price(EUR) : €4550.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ustekinumab | CNTO-1275; C-340 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Arthritis, Juvenile; Crohn Disease; Dermatitis, Atopic; Plaque psoriasis; Hidradenitis Suppurativa; Uveitis; Common Variable Immunodeficiency; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Psoriasis; Lupus Erythematosus, Systemic; Liver Cirrhosis, Biliary; Multiple Sclerosis; Sjogren's Syndrome; Pouchitis; Ichthyosis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Diabetes Mellitus, Type 1; Polymyositis | Details |
Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™ | Japan | Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA | United States | Crohn Disease; Plaque psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ustekinumab biosimilar (Bio-Thera ) | BAT-2206 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Autoimmune Diseases; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Psoriasis | Details |
Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
Ustekinumab biosimilar(Biocon) | Phase 3 Clinical | Biocon Biologics Ltd | Psoriasis | Details | |
Ustekinumab biosimilar(CSPC Pharma) | SYSA-1902 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
Apilimod mesilate | AIT-101; STA-5326-mesylate; LAM-002; STA-5326; LAM-002A | Phase 2 Clinical | Synta Pharmaceuticals Corp, Lam | Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Common Variable Immunodeficiency; Crohn Disease; Amyotrophic Lateral Sclerosis | Details |
NSC-733972 | M-032; M032-H SV-1; NSC-733972 | Phase 2 Clinical | University Of Alabama At Birmingham | Glioblastoma; Gliosarcoma; Astrocytoma | Details |
Tavokinogene telseplasmid (OncoSec Medical) | pIL-12; DNA IL-12 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Hepatocellular; Mycosis Fungoides; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Colorectal Neoplasms; Breast Neoplasms; Hepatitis B; Prostatic Neoplasms; Small Cell Lung Carcinoma; Hemorrhagic Fever, Ebola; Pancreatic Neoplasms; Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
INO-9012/Human papillomavirus vaccine | INO-3112; INO-9012/VGX-3100; VGX-3100/INO-9012 | Phase 2 Clinical | University Of Pennsylvania, Astrazeneca Plc, Inovio Pharmaceuticals Inc | Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Vaginal Neoplasms; Papillomavirus Infections; Neoplasms; Carcinoma, Transitional Cell; Vulvar Neoplasms; Oropharyngeal Neoplasms; Penile Neoplasms; Uterine Cervical Neoplasms | Details |
T-3011 | T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 | Phase 2 Clinical | Immvira Co Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Squamous Cell; Lymphoma; Endometrial Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Sarcoma; Liver Neoplasms; Ascites; Mesothelioma; Small Cell Lung Carcinoma; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
PDS-0301 | M-9241; MSB-0010360; MSB0010360; PDS-0301 | Phase 2 Clinical | Emd Serono Inc, Merck Serono, National Cancer Institute | Prostatic Neoplasms; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Urogenital Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Cholangiocarcinoma; Vulvar Neoplasms; Intestinal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Papillomavirus Infections; Rectal Neoplasms; Carcinoma; Anus Neoplasms | Details |
STX-001 | STX-001 | Phase 2 Clinical | Massachusetts Institute Of Technology | Solid tumours | Details |
DF-6002 | DF-6002 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours; Neoplasms | Details |
Recombinant Human nsIL12 Oncolytic Adenovirus (Beijing Haute Biotechnology) | BioTTT-001; BioTTT001 | Phase 2 Clinical | Beijing Bio-Targeting Therapeutics Technology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms | Details |
Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus(CNBG) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Solid tumours; Liver Neoplasms; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Cholangiocarcinoma; Carcinoma, Hepatocellular | Details |
Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Urogenital Abnormalities; Carcinoma, Hepatocellular; Precancerous Conditions; Lung Neoplasms; Vulvar Diseases; Hepatitis C; Colorectal Neoplasms; Squamous Intraepithelial Lesions of the Cervix; Breast Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Liver Neoplasms; Neoplasms, Glandular and Epithelial; Papillomavirus Infections; Pancreatic Neoplasms; Glioblastoma; Esophageal Neoplasms; Stomach Neoplasms; Hemorrhagic Fever, Ebola; Hepatitis, Chronic; Head and Neck Neoplasms; HIV Infections; Ovarian Neoplasms | Details |
Veledimex | INXN-1001; AD-1001 | Phase 1 Clinical | Ziopharm Oncology Inc | Glioblastoma; Brain Neoplasms; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Melanoma | Details |
XTX-301 | XTX-301 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Breast Neoplasms | Details |
MVR-C5252 | C-5252; MVR-C5252 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma | Details |
WTX-330 | WTX-330 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin | Details |
WTX-124 | WTX-124 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasm Metastasis | Details |
IL-12 DNA(NIAID) | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
SW-0715 | SW-0715 | Phase 1 Clinical | Stemirna Therapeutics | Solid tumours | Details |
KGX-101 | KGX-101; KGX101; KGX-101(IL-12-Fc融合蛋白); KGX-101(改造优化的细胞因子IL12前药分子) | Phase 1 Clinical | Shanghai KangaBio Co Ltd | Solid tumours; Neoplasms | Details |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
JCXH-211 | JCXH-211 | Phase 1 Clinical | Jiachen Xihai(Hangzhou)Biotechnology Co Ltd | Solid tumours; Skin Neoplasms | Details |
EGFR IL12 CART | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
XmAb-662 | XmAb-662 | Phase 1 Clinical | Xencor Inc | Solid tumours; Neoplasms | Details |
MEDI-1191 | MEDI-1191; MEDI1191 | Phase 1 Clinical | Moderna Inc | Solid tumours; Neoplasms | Details |
Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
MEDI-9253 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Neoplasms | Details | |
INXN-2001 | Ad-IL-12; ZIN-ATI-001; Ad-RTS-hIL-12; Ad-RTS-mIL-12; INXN-2001; Ad-RTS-IL-12; INXN-2001 (Ad-RTS-IL-12) | Phase 1 Clinical | Ziopharm Oncology Inc | Glioblastoma; Breast Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma; Astrocytoma; Melanoma | Details |
This web search service is supported by Google Inc.